U.S. drugmaker Pfizer PFE.N is going “all in” to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the JPMorgan ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new drug last month and ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical ...

As generative AI continues to reshape the legal and corporate landscapes, actionable steps should now be at the forefront of crisis communication plans to help firms combat the rapid spread of ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

The city of Greensboro has joined a national litigation campaign suing the nation's three largest pharmacy benefit managers and three largest insulin manufacturers with the goal of lowering insulin pr ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...